Coronavirus

Findings of JAMA Network Open analysis reveal effects of interventions designed to prevent spread.

The first study of COVID-19 vaccination status among romantic couples found 15.63% were in disagreement over whether to receive the vaccine.

“Deltacron,” a COVID-19 strain with genes from both the Delta and Omicron variants, appears to have been circulating since the beginning of the year.

Popular pain and fever-reducing drugs can have unintended consequences when it comes to infectious diseases.

Patients hospitalized during the COVID-29 pandemic for unrelated conditions were 20% more likely to die than in the prepandemic period.

A large surveillance study of 2 symptom-reporting databases found side effects after Moderna or Pfizer-BioNTech COVID-19 vaccination were frequently nonserious and resolved within 1-2 days.

The company is examining its antiviral pill for children 6 to 17 years of age in combating COVID-19.

Study with Medicare beneficiaries found those at highest risk of severe COVID-19 among least likely to receive monoclonal antibody treatment.

Even a mild COVID-19 infection can change the brain. People infected had a greater reduction in brain volume and performed worse on cognitive tests than those who did not contract COVID-19.

Investigators finding high risk for cardiovascular complications post-acute COVID-19 urge increased monitoring and preparedness.

Final analysis of phase 3, placebo-controlled trial confirms efficacy and safety of single-dose adenoviral vector vaccine against COVID-19.

Black Americans were more likely than White Americans to have a significant decrease in COVID-19 vaccine hesitancy over time.

Associations between social determinants of health (SDOH) and COVID-19 mortality varied across racial and ethnic groups and community types.

This week, one of the m-RNA COVID-19 vaccine’s effectiveness was shown to drop from 68% to 12% in children 5-11 years old within a month. This data raises concerns of what should be done to protect this pediatric population.

One study found people were more likely to take the COVID-19 pandemic seriously when they saw the overall number of infections, as opposed to being presented with only new daily cases.

However, those that do have significant influence—and may have affected vaccination rates and treatment use, research suggests.

Few patients hospitalized for COVID-19 developed concurrent infectious diseases or required antibiotics.

Minnesota hospitals established to care exclusively for COVID-19 patients saw lower rates of mortality than general hospitals.

“COVID-19 need no longer control our lives,” President Biden said, detailing a plan to immediately provide free antiviral pills to anyone who tests positive.

A major genetic risk factor for COVID-19, inherited from Neandertals, significantly reduces the risk of contracting HIV.

Due to decreased efficacy against the Omicron variant, the FDA is now recommending approved populations receive a higher dose of Evusheld (tixagevimab and cilgavimab) for COVID-19 prevention.

New research points to vaccine effectiveness against infection dropping from 68% to 12% in this pediatric population within a month.

A pair of studies released last weekend found the COVID-19 pandemic was caused by at least 2 zoonotic transmission events at the Huanan Seafood Wholesale Market in Wuhan, China.

Although it is possible, a small Danish study showed the majority of these cases were often mild and in unvaccinated individuals.

The waning of protection after full vaccination matters more than the advent of the more transmissible Delta variant in subjects who tested positive for COVID-19.

This is broken down into counties that are either high, medium, or low level categories. Many areas of the US are able to go without masks.

Among fully vaccinated people, being older than 60 years and having kidney failure were the only consistent predictors of severe COVID-19 disease and death.

The federal agency is going to lay out recommendations for states.

This is the first authorized COVID-19 vaccine that was developed by a Canadian-based company, and the first that used a plant-based protein technology.

CDC expands recommended timeline between second and third COVID-19 vaccine to 8 weeks for people 12 years and older, especially for young men, to reduce the risk of myocarditis.